Associates Iv L P Venrock H... Net Worth

The estimated Net Worth of Associates Iv L P Venrock H... is at least $782 mil dollars as of 24 October 2019. Associates H owns over 1,093,847 units of Bellerophon Therapeutics Inc stock worth over $257,407 and over the last 6 years Associates sold BLPH stock worth over $525,047.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Associates H BLPH stock SEC Form 4 insiders trading

Associates has made over 2 trades of the Bellerophon Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Associates sold 1,093,847 units of BLPH stock worth $525,047 on 24 October 2019.

The largest trade Associates's ever made was selling 1,093,847 units of Bellerophon Therapeutics Inc stock on 24 October 2019 worth over $525,047. On average, Associates trades about 618,352 units every 137 days since 2019. As of 24 October 2019 Associates still owns at least 6,435,173 units of Bellerophon Therapeutics Inc stock.

You can see the complete history of Associates H stock trades at the bottom of the page.

Insiders trading at Bellerophon Therapeutics Inc

Over the last 10 years, insiders at Bellerophon Therapeutics Inc have traded over $8,853,497 worth of Bellerophon Therapeutics Inc stock and bought 9,412,012 units worth $57,370,250 . The most active insiders traders include Robert Nelsen, Adam Weinstein y Associates Iv L P Venrock H.... On average, Bellerophon Therapeutics Inc executives and independent directors trade stock every 61 days with the average trade being worth of $10,679. The most recent stock trade was executed by Capital Management Lp Puiss... on 13 October 2023, trading 1,076,841 units of BLPH stock currently worth $107,684.

What does Bellerophon Therapeutics Inc do?

bellerophon therapeutics is a clinical-stage biotherapeutics company focused on developing innovative products combining novel drugs and devices in the treatment of cardiopulmonary and cardiac diseases. our mission is to develop well-studied molecules deployed through innovative delivery systems to treat diseases with significant unmet clinical need.

Complete history of Associates H stock trades at Bellerophon Therapeutics Inc

Bellerophon Therapeutics Inc executives and stock owners

Bellerophon Therapeutics Inc executives and other stock owners filed with the SEC include:

• Fabian Tenenbaum,
  Chief Executive Officer, Chief Financial Officer, Chief Business Officer, Director
• Peter Fernandes,
  Chief Regulatory and Safety Officer
• Assaf Korner,
  Chief Financial Officer, Secretary
• Peter Fernandes M. Pharm,
  Interim Principal Exec. Officer, Chief Regulatory & Safety Officer
• Martin Dekker,
  Vice President - Engineering and Manufacturing
• Jonathan Peacock,
  Chairman of the Board
• Crispin Teufel,
  Independent Director
• Mary Cloyd,
  Independent Director
• Naseem Amin,
  Independent Director
• Andre Moura,
  Independent Director
• Theodore Wang,
  Independent Director
• Scott Bruder,
  Independent Director
• Matthew Bennett,
  Independent Director
• Wassim Fares,
  Chief Medical Officer.
• Amy Edmonds,
  Vice President - Clinical Operations and Administration
• Parag Shah,
  Vice President - Business Operations
• Dr. Edwin L. Parsley,
  Acting Chief Medical Officer
• Dr. Parag Suresh Shah,
  VP of Bus. Operations
• Nicholas Laccona,
  Principal Financial & Accounting Officer and Sec.
• Cross Border Opportunities ...,
  
• Megan Schoeps,
  Principal Financial Officer
• Matthew S. Holt,
  Director
• Deborah Quinn,
  Chief Medical Officer
• Adam Weinstein,
  Director
• Daniel Tasse,
  Director
• Mountain Investments Ii, Ll...,
  
• Life Science Opportunities ...,
  
• Associates Iv L P Venrock M...,
  
• Associates Iv L P Venrock H...,
  
• Associates Iv L P Venrock P...,
  
• Associates Iv L P Shah Nimi...,
  
• Associates Iv L P Venrock P...,
  
• Associates Iv L P Venrock H...,
  
• Jens Luehring,
  Director
• Venture Fund Vi Lparch Vent...,
  
• Martin Meglasson,
  Chief Scientific Officer
• Mountain Investments Ii, Ll...,
  
• Manesh Naidu,
  Chief Business Officer
• Robert Nelsen,
  Director
• North America, Inc. Linde,
  10% owner
• Amit Agrawal,
  Chief Operating Officer
• David Abrams,
  Treasurer
• R Scott Huennekens,
  Director
• Reinilde Heyrman,
  Chief Clinical Dev. Officer
• Associates Iv L Pvenrock En...,
  
• Life Science Opportunities ...,
  
• Nicholas Laccona,
  FINANCIAL OFFICER, (PFO & PAO)
• Capital Management Lp Puiss...,
  
• Life Science Opportunities ...,
  
• Bobae Kim,
  VP Reg. Affairs & Quality